Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,582.50
Bid: 1,582.50
Ask: 1,583.00
Change: -35.50 (-2.19%)
Spread: 0.50 (0.032%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK sets new environmental goals

3 Nov 2020 08:00

RNS Number : 0736E
GlaxoSmithKline PLC
03 November 2020
 

Issued: GlaxoSmithKline plc, 3 November 2020, London UK

 

GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030

 

 

 

Increasing scientific evidence[1] demonstrates that climate change and nature loss are impacting the world and human health in many ways, including: extreme heat contributing to deaths from diseases; increased spread of infectious diseases and air pollution exacerbating respiratory diseases.

 

Today, GSK has announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030.

 

The new goals form part of GSK's Trust priority and ESG approach, which support the company's aim to create long-term value for shareholders and meet the needs of society. Over the next decade, GSK will invest in measures to reduce its environmental impact, in restoration programmes to balance the remaining impact that the company cannot reduce and aim to put back into nature more than the company takes out.

 

Underpinning these goals, the company has set new targets across its different businesses, including: 100% renewable electricity usage and good water stewardship at all GSK sites; 100% of materials sustainably sourced and deforestation free and transitioning to 100% usage of electric vehicles by GSK sales representatives worldwide. More information on the goals and the targets are available on gsk.com.

 

Emma Walmsley, Chief Executive Officer, GSK, said, "As a global healthcare company, we want to play our full part in protecting and restoring the planet's health, in order to protect and improve people's health. Improving the environmental sustainability of our business also makes us more resilient, protecting our operations, so we can deliver the products that patients and consumers rely on.

 

"As part of our Trust priority and ESG commitments, we are announcing a new level of ambition on environmental sustainability, with the twin goals of ensuring the new GSK has a net zero impact on climate and a net positive impact on nature by 2030.

 

"All of us working at GSK are very motivated by the challenge of delivering these new goals. Meeting these goals will require working closely with others, including our suppliers, customers, consumers and patients, and we are grateful for their support."

 

The new goals apply principally to GSK's Biopharma business and portfolio. The company's Consumer Healthcare business will also contribute towards these goals through delivery of its own targets, whilst it is part of GSK. Post separation, the new Consumer Health company will be a world-leading business and its new targets reflect this, representing a significant new level of ambition, to drive positive environmental change and help improve everyday health.

 

GSK has long been committed to reducing its environmental impact and was one of the first pharmaceutical companies to set ambitious environment targets in 2010. Since then, across its operations GSK has reduced carbon emissions by 34%, waste to landfill by 78% and total water use by 31% (2019 figures).

 

The Science Based Targets Initiative has accredited that GSK's new carbon targets align to a 1.5° pathway - in line with the most ambitious goal of the Paris Agreement. The company will align to the Science Based Targets Network approach to measure its impact on nature and will seek to accredit its nature target when the methodology is finalised.

 

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

 

 

GSK enquiries:

Media enquiries:

Simon Steel

+44 (0) 20 8047 5502

(London)

Tim Foley

+44 (0) 20 8047 5502

(London)

Kristen Neese

+1 804 217 8147

(Philadelphia)

Kathleen Quinn

+1 202 603 5003

(Washington DC)

Analyst/Investor enquiries:

Sarah Elton-Farr

+44 (0) 20 8047 5194

(London)

Sonya Ghobrial

+44 (0) 7392 784784

(Consumer)

Danielle Morris

+44 (0) 20 8047 7562

(London)

James Dodwell

+44 (0) 20 8047 2406

(London)

Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

Frannie DeFranco

+1 215 751 4855

(Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSK's "Principal risks and uncertainties" section of the Q3 Results and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS


[1] The 2019 report of the Lancet Countdown on health and climate change ensuring that the health of a child born today is not defined by a changing climate

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUOVBRRUUARRA
Date   Source Headline
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
12th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20237:00 amRNSZantac (ranitidine) litigation
10th Oct 202311:00 amRNSHolding(s) in Company
9th Oct 20237:00 amRNSGSK and Zhifei announce vaccine partnership
6th Oct 20237:00 amRNSGSK completes sale of shares in Haleon plc
5th Oct 20234:46 pmRNSGSK announces intention to sell shares in Haleon
2nd Oct 20233:00 pmRNSTotal Voting Rights
27th Sep 20233:00 pmRNSDirectorate Change
25th Sep 20237:00 amRNSGSK RSV vaccine for older adults approved in Japan
21st Sep 20233:30 pmRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSApretude for PrEP receives EMA approval
18th Sep 20237:00 amRNSFDA approves Ojjaara (momelotinib)
13th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20237:00 amRNSMomelotinib filing accepted in Japan
1st Sep 20233:00 pmRNSTotal Voting Rights
1st Sep 20237:00 amRNSGSK’s Nucala CRSwNP submission accepted in Japan
31st Aug 20233:16 pmRNSHolding(s) in Company
31st Aug 20233:14 pmRNSHolding(s) in Company
25th Aug 20233:30 pmRNSDirector/PDMR Shareholding
23rd Aug 20233:30 pmRNSDirector/PDMR Shareholding
23rd Aug 20237:00 amRNSShingrix data demonstrate 100% efficacy in China
22nd Aug 20233:30 pmRNSDirector/PDMR Shareholding
10th Aug 20233:30 pmRNSDirector/PDMR Shareholding
9th Aug 20233:30 pmRNSDirector/PDMR Shareholding
8th Aug 20231:05 pmRNSPublication of Base Prospectus
1st Aug 20233:00 pmRNSTotal Voting Rights
31st Jul 20236:00 pmRNSFDA approves new use for Jemperli plus chemo
31st Jul 20233:30 pmRNSDirector/PDMR Shareholding
28th Jul 20233:30 pmRNSDirector/PDMR Shareholding
26th Jul 20237:00 amRNS2nd Quarter Results
24th Jul 20237:00 amRNSCabotegravir LA for PrEP receives positive CHMP
20th Jul 20233:30 pmRNSDirector/PDMR Shareholding
17th Jul 20233:30 pmRNSDirector/PDMR Shareholding
13th Jul 20233:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20233:00 pmRNSTotal Voting Rights
28th Jun 20233:43 pmRNSGSK completes acquisition of BELLUS Health
27th Jun 20237:00 amRNSFDA Fast Track for Gonorrhoea Vaccine Candidate
26th Jun 20237:05 amRNSShingrix approved in Japan for adults 18 and over
26th Jun 20237:00 amRNSGSK daprodustat gains positive EMA CHMP opinion
23rd Jun 20233:37 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:33 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20237:00 amRNSStatement: Zantac (ranitidine) litigation
22nd Jun 20237:00 amRNSGSK’s Arexvy recommended by ACIP
21st Jun 20237:00 amRNSSeason two data for GSK Arexvy RSV OA vaccine
16th Jun 20237:00 amRNSExtension of FDA review period for momelotinib
12th Jun 20233:30 pmRNSDirector/PDMR Shareholding
7th Jun 20237:00 amRNSEU authorisation of GSK’s RSV vaccine Arexvy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.